Printer Friendly

MOLECULAR BIOSYSTEMS INC. ANNOUNCES NEW HIRES AND PROMOTIONS

 MOLECULAR BIOSYSTEMS INC. ANNOUNCES NEW HIRES AND PROMOTIONS
 SAN DIEGO, Jan. 24 /PRNewswire/ -- Molecular Biosystems Inc. (NYSE: MB) (MBI) announced today the following new hires and promotions.
 Recent new hires:
 Steven Lawson has been appointed vice president legal affairs and general counsel. Lawson will provide support in areas such as contract negotiations and compliance, employment issues, trade regulations, patents, licensing and new business development. He was most recently a partner in the law firm of Johnson and Colmar in Chicago, MBI's current main outside counsel. Lawson received his juris doctorate from Columbia University Law School and his bachelor of arts degree from Yale University.
 Cynthia Mendez joins MBI from Cipher Data Products Inc. as MBI's new director of human resources. Mendez, who has 20 years experience in the field of human resources, is a member of the Human Resources Executive Committee of the American Electronics Association, International Society of Human Resources Management, and The Planning Forum. Her role at MBI will include overall responsibility for human resources, including development and implementation of compensation programs, training programs and strategic planning.
 Recent promotions:
 Peter Westkaemper has been promoted from vice president of operations to group vice president, operations. Westkaemper oversees MBI's operations, manufacturing, regulatory affairs, QA/QC, R&D and clinical departments. He has been with MBI since January 1987. His previous experience includes clinical trial direction at Centocor and QA management at Syva.
 John Young has been promoted from director of manufacturing to vice president, operations. Young joined MBI in 1988 with 14 years of pharmaceutical experience, including management positions at Baxter Healthcare Corp., ICI Inc., Stuart Pharmaceutical Laboratories and American Hospital Supply. He is responsible for the manufacture of MBI's flagship ultrasound contrast agent, Albunex (R), currently awaiting FDA approval.
 James Barnhart, Ph.D, has been placed in charge of MBI's research and development efforts for the Imaging Division. Barnhart's focus will be on strategic planning and licensing activities. Barnhart joined MBI in 1988 from research and teaching posts at UCSD/Department of Radiology and Southwestern Medical School/Departments of Internal Medicine and Physiology. Barnhart has almost 20 years of experience in imaging and contrast media.
 Sherry Mesman has been promoted to chief accounting officer and treasurer. Mesman, a C.P.A., joined MBI from the San Diego office of Arthur Anderson & Co. in 1989 and is currently responsible for MBI's accounting and MIS operations. Ruth Coolong has also been named assistant treasurer in support of Mesman.
 -0- 1/24/92
 /CONTACT: Beth Wallace of Molecular Biosystems, 619-452-0681/
 (MB) CO: Molecular Biosystems Inc. ST: California IN: MTC SU: PER


AL-CH -- SD001 -- 3336 01/24/92 13:26 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 24, 1992
Words:438
Previous Article:LISC ANNOUNCES $128 MILLION HOUSING FUND; PHILADELPHIA TO RECEIVE $4 MILLION FOR AFFORDABLE HOUSING
Next Article:FIRST QUARTER DIVIDEND ANNOUNCED BY WACHOVIA CORPORATION
Topics:


Related Articles
MBI AND IMCERA'S MALLINCKRODT MEDICAL UNIT ANNOUNCE FILING OF NDS FOR ALBUNEX(R)
Phase 3 Clinical Findings Submitted on use of ALBUNEX(R) for Fallopian Tube Patency
Molecular Biosystems, Mallinckrodt File For PMA for Next Generation Ultrasound Imaging Agent, FS069
Molecular Biosystems, Mallinckrodt Expand Partnership for Marketing of FS069
Molecular Biosystems, Mallinckrodt Announce Restructuring of OPTISON(R) Agreement.
Molecular Devices and LJL BioSystems Agree to Merge.
Molecular Devices and LJL Biosystems Set Date of Special Meetings.
Molecular Devices and LJL BioSystems Announce Termination of HSR Act Waiting Period.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters